Agreement is part of Daiichi Sankyo’s five-year mid-term strategy to transform to a structure primarily focused on patented drugs
TOKYO & BASKING RIDGE, N.J., January 18, 2022 –( BUSINESS WIRE )–Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) have entered into an agreement with Cosette Pharmaceuticals, Inc. whereby Daiichi Sankyo divested and Cosette acquired rights for manufacturing, commercialization, and certain other rights for the following products in the U.S.: AZOR ® (amlodipine/olmesartan medoxomil)
BENICAR ® (olmesartan medoxomil) BENICAR HCT ® (olmesartan medoxomil/hydrochlorothiazide) EFFIENT ® (prasugrel) EVOXAC ® (cevimeline HCL) TRIBENZOR […]
Click here to visit source. finance.yahoo.com